bioRxiv preprint doi: https://doi.org/10.1101/354290; this version posted June 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. L-norvaline reverses cognitive decline and synaptic loss in a murine model of Alzheimer's disease. Baruh Polis1,2*, Kolluru D Srikanth2, Evan Elliott3, Hava Gil-Henn2 , Abraham O. Samson1 1 Drug Discovery Laboratory, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel. 2 Laboratory of Cell Migration and Invasion, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel. 3 Laboratory of Molecular and Behavioral Neuroscience, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel. * Correspondence should be addressed to: Baruh Polis, The Azrieli Faculty of Medicine, Bar-Ilan University, 8th Henrietta Szold Street, P.O. Box 1589, Safed 1311502, Israel. Phone: +972525654451, e-mail:
[email protected] Keywords: Alzheimer’s disease, L-norvaline, L-arginine, arginase, memory, amyloid beta, ribosomal protein S6 kinase beta-1, mTOR. 1 bioRxiv preprint doi: https://doi.org/10.1101/354290; this version posted June 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The urea cycle plays a role in the pathogenesis of Alzheimer’s disease (AD).